Nuevolution A/S is a unique company poised to revolutionize lead discovery by utilising its proprietary Chemetics® technology to synthesize and identify hundreds of diverse drug leads to pharmaceutically important therapeutically targets.
Chemetics® represents the ultimate “convergent” fragment based lead discovery technology. It is a unique, patent protected hybrid of proven wet chemistry and molecular biology that enables the rapid synthesis and selection of ligands from millions to billions of drug-like compounds in a single test tube.
Financials
| Date | Type | Amount | Investors | Valuation |
|---|---|---|---|---|
| 06/01/12 | Other | 13.8M | Industrifonden, Sunstone Capital, SEB Venture Capital, SEB Utvecklingsstiftelse. | Unknown |